Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Bausch Health Companies Inc is a drug manufacturers-specialty & generic business based in the US. Bausch Health Companies shares (BHC) are listed on the NYSE and all prices are listed in US Dollars. Bausch Health Companies employs 21,700 staff and has a trailing 12-month revenue of around USD$8 billion.
|Latest market close||USD$20.56|
|52-week range||USD$11.15 - USD$30.39|
|50-day moving average||USD$19.7665|
|200-day moving average||USD$17.9744|
|Wall St. target price||USD$27.22|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.61|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-12.51%|
|1 month (2020-12-18)||-0.82%|
|3 months (2020-10-16)||20.16%|
|6 months (2020-07-17)||13.84%|
|1 year (2020-01-17)||-32.03%|
|2 years (2019-01-18)||-10.96%|
|3 years (2018-01-18)||22.1|
|5 years (2016-01-15)||88.7|
Valuing Bausch Health Companies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch Health Companies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bausch Health Companies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.1 billion.
The EBITDA is a measure of a Bausch Health Companies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$8 billion|
|Operating margin TTM||15.3%|
|Gross profit TTM||USD$6.3 billion|
|Return on assets TTM||2.43%|
|Return on equity TTM||-119.69%|
|Market capitalisation||USD$7.2 billion|
TTM: trailing 12 months
There are currently 14.0 million Bausch Health Companies shares held short by investors – that's known as Bausch Health Companies's "short interest". This figure is 12.6% down from 16.0 million last month.
There are a few different ways that this level of interest in shorting Bausch Health Companies shares can be evaluated.
Bausch Health Companies's "short interest ratio" (SIR) is the quantity of Bausch Health Companies shares currently shorted divided by the average quantity of Bausch Health Companies shares traded daily (recently around 2.8 million). Bausch Health Companies's SIR currently stands at 4.92. In other words for every 100,000 Bausch Health Companies shares traded daily on the market, roughly 4920 shares are currently held short.
However Bausch Health Companies's short interest can also be evaluated against the total number of Bausch Health Companies shares, or, against the total number of tradable Bausch Health Companies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bausch Health Companies's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Bausch Health Companies shares in existence, roughly 40 shares are currently held short) or 0.0448% of the tradable shares (for every 100,000 tradable Bausch Health Companies shares, roughly 45 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bausch Health Companies.
Find out more about how you can short Bausch Health Companies stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bausch Health Companies.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 41.19
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bausch Health Companies's overall score of 41.19 (as at 01/01/2019) is pretty weak – landing it in it in the 89th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bausch Health Companies is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.36/100
Bausch Health Companies's environmental score of 3.36 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bausch Health Companies is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 23.99/100
Bausch Health Companies's social score of 23.99 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bausch Health Companies is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.84/100
Bausch Health Companies's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bausch Health Companies is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bausch Health Companies scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Bausch Health Companies has a damaged public profile.
|Total ESG score||41.19|
|Total ESG percentile||88.8|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||4|
We're not expecting Bausch Health Companies to pay a dividend over the next 12 months.
Bausch Health Companies's shares were split on a 2:1 basis on 16 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bausch Health Companies shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bausch Health Companies shares which in turn could have impacted Bausch Health Companies's share price.
Over the last 12 months, Bausch Health Companies's shares have ranged in value from as little as $11.15 up to $30.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bausch Health Companies's is 1.41. This would suggest that Bausch Health Companies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.